Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA Places Top Priority on
June 26, 2006
- Takeda Ties-Up with Cephalon
June 26, 2006
- JPMA
June 26, 2006
- Mediceo Paltac to Acquire
June 26, 2006
- NEW PRODUCTS
June 26, 2006
- Lilly Initiates PIII Study
June 26, 2006
- Amended PAL Will Create New Business
June 26, 2006
- HMW Fucoidan Inhibits
June 26, 2006
- Healthcare Reform-related Bill Passes the Diet
June 26, 2006
- 8th Meeting of JSCPS
June 26, 2006
- New Drug Data Protection
June 26, 2006
- R&D NEWS IN BRIEF
June 26, 2006
- SURVEY 4 articles
June 19, 2006
- SELF-MEDICATION NEWS IN BRIEF
June 19, 2006
- Abilify to Accelerate Otsuka's
June 19, 2006
- MIYARISAN Licenses
June 19, 2006
- Diet Approves PAL Amendment
June 19, 2006
- Respiratory Drugs to Be
June 19, 2006
- NHI Price Listing Announced for
June 19, 2006
- BUSINESS NEWS IN BRIEF
June 19, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…